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Abstract 
This study demonstrates the preparation and characterization of ibuprofen (IBP) 
microparticles with some excipients by a controlled crystallization technique with improved 
dissolution performance. Using the optimum concentrations Pluronic F127 (Pl F127), 
hydroxypropyl methyl cellulose (HPMC), D-mannitol and L-leucine in aqueous ethanol, the 
IBP microparticles were prepared.  The dissolution tests were performed in phosphate buffer 
saline (PBS) using a USP dissolution tester at 37°C. The Raman spectroscopy was used to 
investigate the interactions and distribution of the IBP with the additives in the microcrystals. 
The prepared IBP microparticles showed higher dissolution compared to that of the smaller sized 
original IBP particles. The Raman data revealed that the excipients with a large number of 
hydroxyl groups distributed around the IBP particle in the crystal, enhanced the dissolution of 
the drug by increasing the drug-solvent interaction presumably through hydrogen bonding. The 
Raman mapping technique gave an insight into the enhanced dissolution behaviour of the 
prepared IBP microparticles and such information will be useful for developing pharmaceutical 
formulations of hydrophobic drugs. The controlled crystallization was a useful technique to 
prepare complex crystals of IBP microparticles along with other additives to achieve the enhanced 
dissolution profile.   
Key words: Ibuprofen, crystallinity, Raman mapping, excipients, dissolution.  
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1. Introduction 
Antisolvent precipitation crystallization (APC) of particles is a technique that provides the 
framework for an appropriate design of micro/nanoparticles to produce engineered particles with 
desired physicochemical properties to meet the requirements in their practical applications1. 
Addition of additives such as mannitol (morphology modifier, discrete particle former), leucine 
(dispersibility enhancer), pluronic (crystal size inhibitor) and hypromellose (HPMC, as 
crystal/agglomerate growth inhibitor) in crystallizing drug particles have been studied 2-7. Using 
Ibuprofen (IBP) as a model drug, this study attempted to prepare IBP micro/nanoparticles with 
these additives for their characterization and to understand the impact of these excipients in the 
formation and dissolution performances of the active drug.  
 
Ibuprofen, a non-steroidal anti-inflammatory drug, is used as various dosage forms in the 
treatment of various diseases.  This drug is poorly water soluble and thereby the rate of 
dissolution from the currently available dosage forms are limited that leads to poor 
bioavailability at high dose. Despite the fact that the IBP is a commonly used high dose 
therapeutic medicine, its poor solubility in aqueous solutions lessens the dissolution and 
absorption rates 8. Crystals of IBU prepared by conventional methods and subsequent 
micronization by milling are very difficult to reduce in particle size for improving the solubility. 
Dry milling is a commonly used technique to reduce particle size and most of the time particles 
tend to deform rather than fragment during the milling process. The heat generated during dry 
milling cause partial melting (as this drug has a low melting point) of the milled particles and 
thereby produce a large number of amorphous particles that tend to form large agglomerates 9. 
The conventional micronization process (i.e. milling, homogenization) with high energy input 
incorporates undesirable particle shape, size, surface charge modifications, and decreased 
crystallinity that affect the physicochemical properties.  
 
Raman microscopy, a non-destructive analytical technique is used in pharmaceutical 
product design for visualization of component distribution in dosage forms10,11 such as tablets12, 
solid dispersion13 and powder mixtures14. Our study demonstrates an anti-solvent crystallization 
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process for the preparation of IBP microparticles with some excipients (HPMC, mannitol, 
leucine and pluronic) to understand their distribution in the microcrystals and subsequent 
dissolution behaviour of the active drug. In this study, we utilized Raman Micro-Spectroscopy 
for mapping of the individual excipients in a powder mixture to identify the distribution of active 
drug among other additives, and their effects on the dissolution of the IBP from the prepared 
microcrystals.  
2. Material and methods 
2.1 Materials  
Ibuprofen (IBP) was used as the active pharmaceutical ingredient in this study. USP grade 
IBP (Part no: 30-1192-1000GM) was purchased from Professional Compounding Chemists of 
Australia Pty Ltd (PCCA, Matraville, NSW 2036), as a high purity racemate of (R)/(S)-(±)-[2-(4-
isobutyl-phenyl) propionic acid] with the empirical formula C13H18O2 and molecular weight 
206.27. Pluronic F127 (Pl F127) is a surfactant copolymer (Poloxamer 407 NF, Part no: 302637-
500GM) and was purchased from PCCA (Matraville, NSW). Hydroxypropyl methyl cellulose/ 
hypromellose (HPMC), used as stabilizer was purchased from Sigma-Aldrich (09963-100 G, 
Lot: BCBG6002V). D-mannitol (C6H8OH6), used as a cryoprotectant and bulking agent was 
purchased from Sigma-Aldrich (Part No: M4-125-500 g, Lot no: SLBJ5312V). L-Leucine 
(C6H13NO2) (Bioultra, ≥ 99.5%), an amphiphilic surfactant used as a dispersive adjuvant was 
purchased from Sigma-Aldrich (Part No: 61819-100 G, Lot No: BCBM2322V). 
Spectrophotometric grade ethanol was purchased from Sigma-Aldrich and deionised/Millipore 
water is available in the laboratory. All the materials were used as received.  
2.2 Methods 
2.2.1 Preparation of HPMC solutions 
Solutions containing 5% w/w HPMC were prepared by adding HPMC powder to a weight 
of water required to make up to one tenth of the final weight. Vigorous agitation was used until 
the powder was dissolved. The solution was then refrigerated for 24 hours at 4°C to allow 
polymer hydration, made up to final weight and stored refrigerated for 72 hours prior to use 15. 
The final solvents of the required concentration of additives were prepared by taking the weighed 
amount of Pl F127, leucine and mannitol powder, made up to the final weight with the 5% 
HPMC solution  and water/aqueous ethanol to give the additives in the concentration range 
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HPMC 0-0.8%, Pl F127 0-1.8%, leucine 0-1.5% and mannitol 0-9%. They were magnetically 
stirred until complete dissolution was observed. 
2.2.2 Anti-solvent precipitation crystallization (APC) method for particle preparation 
The method for particle preparation was the anti-solvent precipitation crystallization (APC) 
by a co-solvent technique 16. This technique involves mixing of two different phases as 
demonstrated in Fig. 1. The first phase (solvent phase) is ethanol with dissolved IBP (30-200 
mg/g) depending on the batch size. The second phase (anti-solvent phase, water) in which IBP is 
practically insoluble contains the dissolved additives. The crystallizer comprises an ultrasonic 
bath (Soniclean 750 HT), the cooler (Julabo, FT 200), the constant temperature heating 
immersion circulator ED (Julabo) and the overhead stirrer (Lab Co.).Various process parameters 
(Table 1) including temperature, concentration of excipients (HPMC, Pl F127, leucine and 
mannitol), batch size, use of ultrasound and stirring speed were varied to get the best size of the 
micro/nanocrystals. The compositions of the prepared particles formulations are given in Table 
2. 
2.2.3 Freeze drying process for particle recovery 
The micro/nano crystal product suspensions were centrifuged at 3500 rpm for 60 minutes 
in Falcon tubes (10ml and 50ml) to remove non-adhering additives. The excess liquid was 
discarded and the remainder was frozen using a deep freezer at -75ºC for 24 hours. These frozen 
semisolids were freeze dried using a lyophilizer (Alpha 1-4 LD plus) at a temperature of -55°C 
and vacuum 1.0 mbar absolute for 24 – 96 hours, depending on the sample volume. 
2.2.4  Particle size reduction by mill micronizer 
A McCrone Micronizing mill was used to mill raw IBP powder down to the similar size 
obtained by controlled crystallization technique. Raw IBP powder was loaded (< 3 g) into the 
micronizer vessels with zirconia beads. Water with > 300 ppm of detergent (2 mL) was used as a 
fluid. Particles with the required size were found after 12 hours of milling. The samples were 
then dried in an oven overnight at 40 °C. 
2.3. Characterization of prepared particles  
2.3.1. Density and flow property measurements 
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The density, angle of repose, Carr’s index and the Hausner ratio of the prepared IBP 
crystals was determined by the methodology published elsewhere 17. Using the Erweka tapped 
density tester, the densities of powders were determined. After observing the initial powder 
volume and mass, the graduated 5 mL measuring cylinder was mechanically tapped, and volume 
readings were taken until no further volume change was observed. A 5 mL graduated cylinder 
was filled with a mass of 1.3 ± 0.3 g of powder sample. Then the cylinder was secured in the 
support of the tapping apparatus and 100, 500 and 1250 taps on the same powder sample were 
carried out, and the corresponding volumes V100, V500 and V1250 were recorded to the nearest 
graduated unit. In this work, the Carr’s index and Hausner ratio was calculated using measured 
values of bulk density () and tapped density (	
) as follows: 
		 = 100 ×	
!"#$$%&'	!()*+
!"#$$%&
                                          (1) 
,-	. = 	
!"#$$%&
!()*+
                                                                                         (2) 
 
The flowability of the samples was determined using the generally accepted scale of flowability 
for the Carr’s index and the Hausner ratio18. Measurements were taken from three replicates of 
each of the formulations. 
2.3.2. Angle of repose 
To form the angle of repose on a fixed base, a 5 mL beaker was used as a base (10 mm 
diameter) to retain the powder (250 ± 0.5 mg). The powder was poured through a funnel (40 mm 
diameter and 65 mm height). The funnel height was maintained at approximately 2 – 4 cm from 
the top of the powder pile which is formed in order to minimise the impact of falling powder on 
the tip of the cone. The angle of repose was determined by measuring the height of the cone of 
powder and calculating the angle of repose, α, from the following equation: 
tan234 =
5	675
8.:×;	
                               (3) 
 
The degree of flowability was determined from the flow properties corresponding to the angles 
of repose17. Measurements were taken from three replicates of each of the formulations. 
2.3.3. Particle size measurement 
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The particle size of the crystallized IBP was measured by the laser diffraction technique 
using a Malvern Mastersizer 3000 equipped with a small volume dispersion unit. It is estimated 
that the relative error in the volume median diameter (VMD) calculated by the Malvern 
Mastersizer is ± 2% 19. Particle size measurements for the finer nanocrystals were done using the 
Zetasizer (NanoZS 90, Malvern Instruments, UK). The suspending media was the saturated IBP 
solution prepared with an equivalent composition to the final crystallization media at 
equilibrium. This media was used as the dispersant in the Malvern 3000 small volume (120 ml) 
dispersion unit stirring at 2000 rpm. A small amount of prepared powder was dispersed in 5.0 
mL of this dispersion media and sonicated for 5 minutes to ensure all particles dispersed in the 
suspension. Few drops of this concentrated suspensions was added dropwise in the dispersion 
unit until the obscuration reached the desired level. The refractive indexes used for IBP and the 
dispersant were 1.43 and 1.33, respectively. The absorption index was 1.2. The mass median 
diameter (MMD, D[v,0.5]) and volume mean diameter (D
 
[4,3]) determined from the output of 
the laser diffraction particle sizing were used as the major size parameter to characterize the 
particle size distributions (PSD). Measurements were taken from three replicates of each of the 
formulations. 
2.3.4. Scanning electron microscope (SEM)  
A Zeiss Sigma scanning electron microscope was used to investigate the morphological 
properties (shape, size and surface) of the IBP crystals. The sample preparation involved fixing 
the powder samples on to a metal stub with the aid of a double sided adhesive tape followed by 
coating for 180 seconds with a LEICA EM SCD005 gold coater. Scanning electron microscopy 
(SEM) was then carried out by loading the sample on the SEM working at 5 KV.  
2.3.5. Drug loading determination 
Quantification of the IBP content in the powder formulation was determined by UV 
spectrophotometer (Thermo Scientific Evolution Array) at a wavelength of 264 nm. Samples 
were prepared by dissolving a known 10-15 mg of powder formulation in a known 10 (± 1) g of 
50% aqueous ethanol solvent system. Complete solution of IBP in the selected solvent system 
was confirmed from the predetermined solubility results.  
2.3.6 Differential scanning calorimetry (DSC) 
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Differential scanning calorimetry (DSC) experiments were carried out in a DSC Q100 
from TA Instruments Explorer Q series. A known small amount of sample (<6 mg) was enclosed 
in a hermetic sealed aluminum pan. A liquid nitrogen cooling system was used in order to reach 
temperatures as low as - 42 °C. Processed and unprocessed IBP samples were scanned from 10 
°C to 110 °C, using a heating rate of 10°C/min. All samples were analysed in triplicate. The 
percent crystallinity is determined using equation 4: 
% Crystallinity = ∆Hm / ∆Hm°× 100%                   (4) 
 
The heats of melting, ∆Hm, determined by integrating the areas (J/g) under the peaks using TA 
instrument Analysis 2000 software. The term ∆Hm° is a reference value and represents the heat 
of melting of the 100% crystalline IBP. It was found that the melting enthalpy of the raw IBP 
powder was 118.4 ± 7.3 J/g which is also in agreement with Nokhodchi and co-workers 3. This 
value was used as the reference value to determine the percentage crystalline phase of IBP in the 
processed formulations with different compositions of additive. 
2.3.7. Powder X-ray diffraction (XRD) 
The crystallinities of the unprocessed and processed IBP were evaluated using an X-ray 
powder diffractometer (XRD). Samples were front pressed into low background quartz holders. 
Diffraction patterns were collected in θ/2θ geometry on a PANalytical X’Pert Pro diffractometer 
(Co Kα) using a W/Si parabolic mirror and 0.09° collimator before the point detector. A 0.25° 
fixed divergence slit, 10 mm mask, 1.4 mm incident anti-scatter slit, and 0.04 rad pre and post 
diffraction Soller slits were used. Patterns were collected from 3 – 75° 2θ at a step size of 0.02° 
for 1 hr. The sample was spun during data collection. An instrument function was determined 
from LaB6 (SRM 660a). Phase identification was performed with Highscore Plus (V4.5, 
PANalytical) using the PDF4+ database (ICDD) and confirmed via Rietveld refinement with 
TOPAS (V5, Bruker). Quantitative phase analysis was performed using TOPAS (v5, Bruker) via 
the Rietveld method. An instrument function determined from LaB6 (NIST SRM 660a) was used 
to model the profile shape. A Lorentzian crystallite size term was refined for each phase to 
account for profile broadening. Refined terms included specimen displacement, scale factor for 
each phase, and unit cell parameters for each phase. The amount of Pl F127 in some samples was 
estimated by the degree of crystallinity method where the numerical area of each phase is used to 
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determine abundances. The Pl F127 was accounted for by modelling a peak at ca. 27° 2θ (most 
obvious feature not modelled) and designating it as the amorphous phase. HPMC phase 
abundance could not be quantified as its concentration in the formulation was too low to identify 
in the XRD curves. XRD patterns of both the processed and unprocessed IBP were compared to 
identify any alteration in their crystallinities. 
 
2.3.8. Raman spectroscopy 
A WITec Alpha 300 series Raman Microscope equipped with a 532 nm laser was used for 
spectral analysis of the individual components and the powder formulations. The purpose of the 
analysis was to identify the IBP component and additives and their distribution by recording 
Raman maps over selected regions of the powder formulations. To prepare the sample for 
mapping a stainless steel cup was piled slightly high with the formulation powder, which was 
then lightly tamped down by placing a coverslip over the top of the cup. The purpose of the 
coverslip was to establish a horizontal region in the sample that would remain in focus over the 
region to be studied. Raman maps were measured by rastering in the horizontal plane in 0.5 µm 
increments over a 20 x 20 µm region of the powder with the focal plane of the microscope set to 
just beneath the coverslip.  Spectra were recorded at each increment with the integration time of 
1s and a laser power of 10 mW. The Raman microscope was calibrated to the 520.5 nm line of a 
silicon wafer. The Zeiss 50× objective with a 0.7 NA used forms a confocal sample volume 
approximating a cylinder of 0.5 µm diameter and 2-3 µm high. The mapping of the powder 
components in the mixture and the spectral analysis including CLS calculations were performed 
using WITec Control Four and Project Four software.   
 
2.3.9. In vitro drug dissolution test  
The USP paddle method (Pharma Test- DT 70) was adopted in 900 mL phosphate buffered 
saline (PBS, pH 7.4) at 100 rpm and 37 °C for each sample. At the fixed time intervals of 2, 6, 
10, 15, 20, 30, 60, 90 and 120 minutes, 5 mL aliquots of the release medium were withdrawn and 
the same amount replaced with the fresh PBS. The drug content in the withdrawn aliquot was 
analyzed by UV spectrophotometry at 221 nm. Percentage drug release versus time data were 
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plotted to establish drug release profiles from the formulations. Three replicates were undertaken 
on each sample. A sample of milled pure IBP (12.5 mg; size  2.8 ± 0.1 µm)  used as the control 
and three processed formulations (F4, F6 and F10, Table 2) equivalent to 12.5 mg of pure IBP 
were selected for dissolution studies as these processed formulations showed better flow 
property.   
2.3.10. Statistical analysis: All statistical analysis was performed using Microsoft Excel (2016).  
 
3. Results and discussions 
3.1 Formulations of the prepared particles  
To evaluate the efficiency of the processed IBP powder in an APC process, 14 different 
formulations were prepared based on the different batch size of crystallization, initial IBP 
concentrations and additive concentrations. It is noted that the additives mentioned in Table 2 are 
the percentages that were dissolved in the crystallization medium for the total batch size and are 
not the additive contents of the crystal product. Each of the products from these formulations was 
characterized for density, flowability, particle size distribution, morphology, and crystallinity. 
F1, F2, F3, F6 and F7 formulations had different batch sizes from the usual 50g. IBP 
concentration was varied from 0.3% to 2% in the formulations F1 to F6. Additive concentrations 
(Pl F127, HPMC, L-leucine and D-mannitol) were varied in other runs. Initially, using different 
batch size (10-50 g) the precipitation experiments were carried out at various stirring speeds 
(500-2000 rpm) with different duration of mixing (30-60 minutes) to produce small particles. 
Based on the initial runs (a large number of raw data are not presented in this article), the best 
parameters were selected to produce reproducible particle size from a fixed batch of the 
formulation containing the fixed amounts of different components. Finally, keeping the constant 
solvent-anti-solvent ratio (1:9), the optimized process parameters demonstrated in Table 1 have 
been selected from these initial studies for the rest of the experiments with varying 
concentrations of other excipients as demonstrated in Table 2 to obtain similar particle size 
presented in Table 3. 
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3.2 Particle size & size distribution 
Particle size and size distribution of the prepared IBU crystals are presented in Table 3. The size 
of particles was affected by the presence of different concentrations of surfactant Pl F127. The 
decrease in size occurred with increased concentration of Pl F123 until 1.2% (F7) in the 
formulations; however, the size increased at 1.8% of Pl F127 (Formulation 9; Suppl Fig. S1). 
Both mannitol and PL F127 aid in reducing particle size. FPO and FMO are the formulations 
without Pl F127 and D-mannitol respectively, and particles grew larger in these formulations due 
to their absence. The literature has shown that mannitol prevents nanoparticle aggregation during 
the drying process. The stabilization of particles during the freeze drying is proposed to occur by 
sugars isolating individual particles in the unfrozen fraction, thereby preventing aggregation 
during freezing above the glass transition temperature, Tg 20. In this case, the transition of the 
substance into a glass is not required for this effect and the spatial separation of particles within 
the unfrozen fraction is sufficient to prevent aggregation20. As a result, the particle size was 
expected to remain stable with no further growth due to aggregation after the drying step.  
3.3 Density, angle of repose & flowability 
The estimation of the bulk density and tapped density (resulting in the Carr’s index and Hausner 
ratio) and also the angle of repose for estimating flowability are given in Table 4. Flowability of 
all the formulations was determined and the effect of the additive and drug concentration on it 
was observed from the obtained results. The purpose of preparing all of these formulations was 
to identify those formulations with smaller particle size for faster dissolution. Table 4 shows that 
formulations F3, F4, F6, F10 and FMO had good flow properties (Angle of Repose, AR): 31-35; 
Carr’s index (CI): 11-15; Hausner ratio (HR): 1.12-1.18), F1, F2 and FLO were passable and the 
rest were poor (Table 4). Of those with good or passable flowabilities; the FPO and FMO 
formulations had larger particle size (D[4,3] > 10 µm) compared to others.   It was expected that 
the additive concentration might have a significant effect on the flow properties of the prepared 
IBP particles due to their hygroscopic nature. L-leucine is a well-accepted dispersive excipient 
for use in pharmaceutical formulations and it has been found to improve the powder flowability 
in several cases due to its anti-adhesive 21,22 functions and surfactant properties 2,23. Hence, to see 
the leucine effect on flowability, its concentration was increased gradually from 0%, through 
0.9%, 1.2% to 1.5% in FLO, F7, F10 and F11 formulations, respectively. However, no specific 
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trend was observed in the flowability according to the values of Carr’s index, Hausner ratio and 
angle of repose (as illustrated by the angle of repose, Table 4). Surprisingly, FLO has no leucine 
but showed a better flowability than those of the formulations containing 1.5% leucine (F7 and 
F11). An optimal amount of leucine is critical to achieving the desired properties of the leucine 
coated particles, as excessive leucine decreases stability with no additional benefits 24. 
Interestingly, an increase in the Pl F127 concentration in the formulations FPO, F8, F7 and F9, 
where concentration of PL F127 was increased from 0% to 0.6%, 1.2% and 1.8%, appeared to 
influence the flowability negatively. A possible reason could be the decreased particle size with 
increasing Pl F127 concentration, caused the flowability to decrease 25. It has been reported that 
the drug particle has a partial amorphous form due to the presence of Pl F127 26, which might 
have influenced the powder flow negatively. Thus, although leucine has remarkable effects, 
other excipients used to prepare the IBP microparticles have no such effect on the flowability of 
the prepared powders.   
3.4 Particle Morphology by SEM 
The particle morphology of the formulations was investigated by scanning electron 
microscopy (SEM). The SEM images of raw IBP, milled raw IBP and all the formulations are 
presented in Fig. 2. The crystal habit of IBP depends on the crystallization conditions such as the 
solvent type and presence of additives2,27. The SEM images show that the commercial raw IBP is 
needle-shaped, whereas the particles crystallized in the presence of various additives are mostly 
of irregular shapes with pores in the agglomerates. In the case of formulation F5, the 
crystallization was carried out in the absence of leucine and mannitol, which resulted in a 
different morphology, with the crystals having rough surfaces comprising flat-shaped IBP 
particles sticking together to make bigger particles. As the SEM images represent the dried form 
of formulation, it is very likely the particles in F5 formulation aggregated/ agglomerated into 
large irregular shapes due to drying without the leucine and mannitol. The morphology of the 
formulations F6, F7, F8, F9, F10, F11, FPO, FLO and FMO with low IBP concentration (0.3%) 
seems to be the agglomerates of IBP microparticles adhering to each other. The IBP particles in 
FMO are seen clearly in the tight agglomerated form of chunky shaped crystals. The images 
revealed that the needle shaped crystals actually represents the crystal habit of D-mannitol in the 
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powder mixtures. However, the IBP particle morphology was significantly influenced by both 
the additive composition and concentration.  
3.5 Raman mapping for excipients distribution in the microcrystals of IBP 
The particle morphology was investigated using Raman spectroscopy to identify each component 
individually and the distribution of the drug particle with the additives in the powder mixture is 
represented in Fig. 3. Image A is formed by merging the component images to give an overall 
impression of distribution of all components in the co-crystal. The individual components such 
as red representing leucine (B); magenta-pluronic F127 (C), green-HPMC (D), yellow-IBP (E), 
and aqua-mannitol (F) are also shown. The Raman images revealed that IBP drug particles are 
surrounded by the additives used. The distribution of Pl F127, HPMC and L-leucine around the 
IBP particle, reflected the interactions of those excipients with the active drug during the APC 
process.  
 
To explore the possible associations between the excipients and IBP, correlation diagrams were 
prepared by plotting the relative concentration of each component vs the IBP concentration for 
each mapped point.  Results are only shown for those points where significant IBP was present.  
Correlation plots for the representative formulation F6 are given in Figs. 4 (A-D).  A broad trend 
to higher leucine corresponding to higher IBP concentrations seen in Figs 4A suggesting a 
positive correlation between the relatively hydrophobic components leucine and IBP. The Pl 
F127 is closely associated with IBP without significant correlation (4B). The presence of 
hydrophilic HPMC (4C) is poorly distributed in regions of high IBP, suggested a negative 
correlation between the cellulose components with extremely hydrophobic IBP. However, the 
hydrophilic mannitol (4D) is distributed in the region of high IBP and very closely associated 
with the drug particle presumably due to hydrogen bonding. These outcomes helped get a clear 
understanding on the solubility/dissolution behavior of the prepared IBP microcrystals.   
3.6  Crystallinity 
The crystallinity of the raw IBP powder, milled IBP powder, additives and the powder 
formulations was examined using differential scanning calorimetry (DSC). The DSC data are 
presented in Figs. 5 A & B). All the formulations produced an endothermic peak in the range of 
74–78°C, which are in agreement (within ± 2.0 °C) with the previous reports which suggest that 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
IBP exists as crystalline solid exhibiting a typical melting range of 75–77 °C; however, the 
melting point of pure IBP is 77.5ºC28. The melting point for pure IBP, HPMC, Pl F127, mannitol 
and leucine had shown a sharp peak before the melting point of the pure IBP drug (Fig. 5A). The 
additive melting peaks confirmed that the presence of mannitol and leucine would not interfere 
with the pure IBP melting peak identification in DSC, but HPMC and Pl F127 could. Fig. 5B 
represents the DSC curves for raw and milled IBP and all the prepared formulations where the 
endothermic peaks for all the formulations, within the melting point range for pure crystalline 
IBP; however, the height of the peaks changed with respect to the IBP content in the 
formulations. The pure, milled IBP particle and formulations with high concentrations of IBP 
(F4 and F5) showed very sharp peaks, whereas the crystals with other additives and low 
concentrations of IBP showed smaller and broader peaks suggesting that the IBP in the prepared 
formulations are both in crystalline and amorphous forms. The pure IBP showed 100% 
crystallinity, milled IPB produced 94.7% crystallinity due to crushing; however, formulations 
(F4 and F5) with 2.0% IBP at varying concentrations of other excipients showed 96-99% 
crystallinity (Suppl Table S1). Other formulations with low concentrations of IBP in presence of 
other excipients at varying concentrations produced more or less 50% amorphous particles.  
3.7 Dissolution studies 
The dissolution profile of the milled raw IBP powder was much slower compared to those 
of the prepared formulations (Fig. 6). Theoretically, it was expected that the smallest particle size 
of the milled ibuprofen (2.8µm, Table 3) compared to the prepared particles would have a higher 
surface area which could enhance the solubility. However, this did not happen presumably due to 
the strong hydrophobic nature of the drug particle. The prepared IBP micropartilces showed 
faster drug release/dissolution (Fig 6). It can be noted that the drug release from F4, F6 and F10 
were 56, 64 and 96%, respectively in first two minutes. The results indicated that the dissolution 
rate of the prepared formulations was significantly faster than that of the milled pure IBP (<50% 
in 2 minutes). The formulations with the higher initial IBP and lower additive concentrations 
have shown a comparatively lower dissolution rate in the first two minutes. Formulation F10 
showed the highest drug release (96%) in the first two minutes. The possible reason could be the 
presence of a higher content of additives (Pl F127 1.2%, L-leucine 1.2%, D-mannitol 9.0% and 
HPMC 0.2%, Table 2) and very low initial drug load (0.3%) in the formulation F10 which 
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favoured the dissolution process by decreasing drug-drug cohesion and increasing the drug-
solvent interaction.  The Raman images (Fig. 3) clearly demonstrated that a large number of 
excipients especially the amphiphilic leucine and hydrophilic HPMC and D-mannitol containing 
a large number of hydrophilic hydroxyl groups are distributed around the IBP particle in the 
microcrystals. This suggests that the hydroxyl groups of these excipients enhanced the 
dissolution of the drug by increasing the drug-solvent interaction. The hydrophilic HPMC (Fig. 
4C) is poorly associated in regions of extremely hydrophobic IBP. However, because of the 
amorphous character and extensive hydrogen-bonded network, it may help increase the 
dissolution by interacting with solvent through hydrogen bonding. In contrast, the hydrophilic 
mannitol (Fig. 4D) is closely associated with IBP which presumably led to the enhanced 
dissolution by hydrogen bonding.The enhanced dissolution of the prepared formulations 
especially the formulation F4 indicated that the presence of the hydrophilic surfactant pluronic 
(Fig. 4B) around the IBU particles (Fig. 3 E) strongly promoted drug wettability by reducing the 
surface tension of the hydrophobic IBP particles. Additionally, the presence of amphiphilic 
surfactant L-leucine in the complex crystal played a significant role in increasing dissolution of 
the drug possibly due to the orientation of hydroxyl groups towards the aqueous solvent, which 
increased the particle-solvent interactions and improved the dissolution process29. The presence 
of hydrophilic surfactant pluronic and amphiphilic leucine around the IBP crystal strongly 
promoted the wettability by reducing the surface tension of the hydrophobic IBP particles 
leading to increased dissolution. Additionally, the amorphous IBP particles in the prepared 
formulations especially the sample F6 (52% crystalline, Suppl Table S1) containing the low 
concentration of IBP (1.0%) showed higher dissolution (Fig. 6), as this particle in the amorphous 
state contained limited crystal lattice interactions or bonds that needed to break for the drug to 
enter solution leading to higher dissolution compared to that of the pure crystals, which has 
greater intermolecular forces in the crystal. Furthermore, the formation of pores in the complex 
microparticles (SEM images Figs 2) increased the surface area and wettability of drug particles 
and led to increasing the solubility/dissolution. On the other hand, the relatively higher cohesive 
forces among the milled pure IBP particles with the smallest size (2.8µm) potentially influenced 
the overall dissolution negatively due to the extreme hydrophobic nature30. The maximum 
release from milled pure IBP was 71%, whereas, from the prepared formulations F4, F6 and F10 
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were 100, 87% and 96%, respectively in 20 minutes. This promising outcome of dissolution 
studies of the prepared microcrystals ensured the superiority of the prepared IBP over pure 
milled drug particles. Therefore, it can be emphasized that the prepared formulations are better 
than the milled IBP in terms of the dissolution behaviour.  The faster dissolution performance of 
the prepared powder formulations would be useful for the development of dosage forms like 
tablet, capsule, suspensions, and formulation for inhalation to achieve an improved 
bioavailability. 
4. Conclusion 
This study reports the preparation of the hydrophobic IBP microparticles along with other 
additives (HPMC, mannitol, leucine and pluronic) by a controlled crystallization technique with 
enhanced dissolution profile. The prepared IBP microparticles showed higher dissolution 
compared to that of the smaller sized original milled IBP particles as the presence of hydrophilic 
excipients in the formulation played a vital role. The Raman spectroscopy used for the first time 
in this study to investigate the interactions and distribution of the IBP with other additives 
present in the microcrystals, clearly demonstrated that a large number of excipients especially the 
amphiphilic leucine and hydrophilic HPMC and D-mannitol containing a large number of 
hydrophilic hydroxyl groups are distributed around the IBP particle. The hydroxyl groups of 
these excipients enhanced the dissolution of the drug by increasing the drug-solvent interaction. 
The hydrophilic HPMC and mannitol associated in regions of extremely hydrophobic IBP in the 
in the microcrystals, they presumably increase the dissolution process by interacting with solvent 
through hydrogen bonding. The Raman mapping technique, which provides the distribution of 
different components in the microcrystals, gave an insight into the enhanced 
solubility/dissolution behaviour of the prepared IBP microparticles. Such information will be 
useful for developing pharmaceutical formulations with better solubility and dissolution 
properties of hydrophobic drugs. 
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Legend for Figures 
 
Fig. 1.  Anti-solvent precipitation crystallization (APC) process for the preparation of IBP 
microparticles. 
 
 
Fig.2. Particle morphology of the raw and milled IBP and formulations F1, F2, F3, F4, F5, 
F6, F7, F8, F9, F10, F11, FLO, FMO and FPO in scanning electron microscopy 
(Magnification: 5.00 K X). 
 
 
Fig.3. Raman images of the microcrystal (A) of a representative formulation F6 with the 
individual components separately coloured: Red for leucine (B); magenta for pluronic F127 
(C), green for HPMC (D), yellow for IBP (E), and aqua for mannitol (F). These images 
demonstrate the way that the drug crystal is surrounded by the excipients.  
 
Fig. 4. Raman correlation plots of formulation F6. A) leucine vs IBP; B) Pl F127 vs IBP; C) 
HPMC vs IBP; and D) mannitol vs IBP. 
 
Fig. 5.  DSC curves for (A) Pluronic F127, HPMC, L-leucine, D-mannitol, raw IBP; (B) 
milled IBP, F1, F2, F3, F4, F5. F6, F7, F8, F9, F10, F11, FPO, FLO, FMO and raw IBP. 
 
 
Fig. 6.  In vitro dissolution of milled raw IBP powder and some formulations prepared by 
APC process. 
 
 
 
Supplementary Figure 
Fig. S1.  The effect of Pl F127 concentration on particle size. The crystallization solution 
contains 0.3% IBP;0.2% HPMC; 0.9% leucine; 9.0% mannitol; 50 g batch (except F7 which 
was 10 g). 
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Tables 
Table 1: Anti-solvent precipitation crystallization (APC) process parameters and optimized 
range of conditions for preparing respirable IBP particles. 
 
Process parameters Condition 
Batch size 10 – 50 g 
Solvent-anti-solvent ratio (solv/anti-solv) 1 : 9 (fixed) 
Stirring speed, rpm 600 - 1200 
Temperature 25 - 30°C 
Ultrasound application 50Hz, max. pulse swept power 180W 
Duration of mixing 30 - 60 minutes 
Drug concentration in organic phase 0.3-2% 
Pl F127 concentration 0-1.8% 
HPMC concentration 0-0.8% 
Leucine concentration 0-1.5% 
Mannitol concentration 0-9% 
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Table 2.   Composition of the different formulations and the amount of additives.  
 
Formulation 
name 
Batch 
size, g 
IBP* 
conc.% 
Leucine*,%, 
(w/w) 
Mannitol*,%, 
(w/w) 
HPMC*,%, 
(w/w) 
Pl 
F127*,%, 
(w/w) 
Drug 
loading 
(%) 
F1 10 1 1.3 4.5 0.4 1.8 72.7 
F2 30 1 0.9 4.5 0.7 1.3 77.9 
F3 10 1 0.9 4.5 0.7 1.3 90.3 
F4 50 2 1 8.4 0.1 0.9 99.8 
F5 50 2 0 0 0.1 0.9 100.0 
F6 10 1 0.9 4.5 0.6 1.2 83.3 
FPO 50 0.3 0.9 9.0 0.2 0 84.7 
F7 10 0.3 0.9 9.0 0.2 1.2 53.2 
F8 50 0.3 0.9 9.0 0.2 0.6 74.6 
F9 50 0.3 0.9 9.0 0.2 1.8 43.9 
FLO 50 0.3 0 9.0 0.2 1.2 83.9 
F10 50 0.3 1.2 9.0 0.2 1.2 73.5 
F11 50 0.3 1.5 9.0 0.2 1.2 52.7 
FMO 50 0.3 0.9 0 0.2 1.2 99.9 
*These are the percentages of drug/additives in total amount of crystallization batch size. F1 to F11 are 
the formulations with different components. FPO represents the formulation without pluronic, FLO represents 
the formulation without leucine, and FMO indicates the formulation without mannitol.  
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Table 3: Particle sizes and distributions of various IBP formulations (units µm± SD, n=3). 
 
Formulation D[v,0.1]  D[v,0.5]  D[v,0.9]  D[4,3] 
F1 2.9 ± 0.1 6.9 ± 0.1 20.4 ± 2.9 9.6 ± 0.8 
F2 3.5 ± 0.1 8.5 ± 0.1 18.0 ± 0.2 9.7 ± 0.1 
F3 4.6 ± 0.1 17.1±0.5 47.9 ± 1.4 22.0 ± 0.4 
F4 3.3 ± 0.6 6.2 ± 0.2 9.3 ± 0.3 6.3 ± 0.2 
F5 4.2 ± 0.3 7.2 ± 0.5 11.3 ± 1.5 7.5 ± 0.5 
F6 2.9 ± 0.5 5.9 ± 0.8 10.7 ± 1.6 6.5 ± 1.1 
FPO 6.1 ± 0.1 11 ± 0.6 18.7 ± 1.3 12.34 ± 1.2 
F7 1.1 ± 0.1 3.9 ± 0.4 9.0 ± 0.9 5.1 ± 0.9 
F8 3.7 ± 0.1 6.8 ± 0.1 11.9 ± 0.1 7.4 ± 0.1 
F9 1.3 ± 0.1 6.1 ± 0.1 12.8 ± 0.3 6.7 ± 0.1 
FLO 3.2 ± 0.1 6.1 ± 0.1 10.1 ± 0.3 6.6 ± 0.6 
F10 1.4 ± 0.2 6.4 ± 0.3 12.9 ± 0.5 7.1 ± 0.2 
F11 1.2 ± 0.0 5.4 ± 0.6 11.8 ± 0.7 6.4 ± 0.4 
FMO 3.7 ± 0.1 8.7 ± 0.1 28.2 ± 1.2 20.9 ± 1.3 
Milled IBP 1.2 ± 0.1 2.8 ± 0.1 4.45 ± 0.2 2.8 ± 0.1 
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Table 4: Powder flow properties obtained from different formulations (Mean ± SD, n=3) 
Formulation Bulk density 
(g/ml) 
Tapped 
density (g/ml) 
Carr’s 
index (%) 
Hausner 
ratio 
Angle of 
Repose (°) 
Flowability 
F1 0.28 ± 0.02 0.36 ± 0.03 21.5 ± 0.3 1.27 ± 0.01 44.0 ± 0.1 Passable 
F2 0.24 ± 0.03  0.28 ± 0.01 23.7 ± 1.0 1.31 ± 0.02 42.0 ± 1.7 Passable 
F3 0.27 ± 0.04  0.35 ± 0.01 11.1 ± 1.0 1.12 ± 0.01 34.2 ± 1.8 Good 
F4 0.29 ± 0.01 0.34 ± 0.01 13.2 ± 0.8 1.15 ± 0.01 33.9 ± 1.1 Good 
F5 0.27 ± 0.03 0.35 ± 0.01 27.1 ± 0.8 1.37 ± 0.01 50.4 ± 0.2 Poor 
F6 0.26 ± 0.01 0.30 ± 0.02 13.9 ± 0.7 1.16 ± 0.01 36.5 ± 1.3 Good 
FPO 0.20 ± 0.02 0.29 ± 0.01 30.8 ± 0.7 1.44 ± 0.01 53.3 ± 0.4 Poor 
F7 0.18 ± 0.05 0.26 ± 0.02 30.1 ± 0.6 1.43 ± 0.01 53.7 ± 1.1 Poor 
F8 0.22 ± 0.03 0.34 ± 0.04 31.1 ± 0.4 1.45 ± 0.01 53.0 ± 0.7 Poor 
F9 0.21 ± 0.02  0.32 ± 0.01 37.5 ± 0.7 1.60 ± 0.02 60.3 ± 1.4 Very poor 
FLO 0.29 ± 0.001 0.36 ± 0.01 18.3 ± 0.6 1.22 ± 0.01 37.5 ± 0.4 Fair 
F10 0.14 ± 0.01 0.16 ± 0.02 13.1 ± 1.0 1.15 ± 0.01 33.9 ± 2.0 Good 
F11 0.18 ± 0.05 0.21 ± 0.03 26.9 ± 0.5 1.37 ± 0.01 53.3 ± 1.1 Poor 
FMO 0.11± 0.01 0.13 ± 0.02 13.7 ± 0.5 1.16 ± 0.01 34.7 ± 1.9 Good 
Milled IBP 0.13 ± 0.03 0.17 ± 0.05 22.7 ±1.0 1.29 ± 0.02 41.8 ± 0.5 Passable 
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